Abstract
Follicular helper T cells (TFH) have specialized properties in promoting normal B cell activation but their role in chronic lymphocytic leukemia (CLL) is unknown. We find that TFH cells are elevated in CLL patients and are phenotypically abnormal, expressing higher levels of PD-1, TIGIT, CD40L, IFNγ and IL-21, and exhibiting abnormal composition of TFH1, TFH2 and TFH17 subsets. Frequencies of CD4-positive T cells expressing TFH1 markers and IL-21 were positively correlated with patient lymphocyte counts and RAI stage, suggesting that accumulation of abnormal TFH cells is concomitant with expansion of the leukemic B cell clone. Treatment with ibrutinib led to normalization of TFH frequencies and phenotype. TFH cells identified in CLL bone marrow display elevated expression of several functional markers compared to blood TFH cells. CLL T cell-B cell co-culture experiments revealed a correlation of patient TFH frequencies with functional ability of their CD4-positive T cells to promote CLL proliferation. Conversely, CLL cells can preferentially activate the TFH cell subset in co-culture. Together our results indicate that CLL development is associated with expansion of abnormal TFH populations that produce elevated levels of cytokines and costimulatory molecules which may help support CLL proliferation.
Highlights
Monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are lymphoproliferative disorders characterized by the presence of abnormal numbers of CD5+ monoclonal B lymphocytes in the blood or tissues [1]
Peripheral blood mononuclear cells collected from CLL patients, MBL patients or age-matched controls were analyzed by multicolor flow cytometry to assess T follicular helper (TFH) cell populations
Together these results indicate that TFH cells are expanded and phenotypically altered in CLL
Summary
Monoclonal B cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are lymphoproliferative disorders characterized by the presence of abnormal numbers of CD5+ monoclonal B lymphocytes in the blood or tissues [1]. The clinical course of CLL patients is heterogeneous and prognostic markers have been developed to predict which patients may have aggressive disease [3]. Independent prognostic markers for CLL include Rai stage, age, IGVH mutational status, b2-microglobulin level and TP53 loss-offunction [1, 3], which are used to calculate the International Prognostic Index [4]. CLL B cells come into close contact with other cells such as stromal cells, which provide signals that promote survival and drug resistance [5]. The lymphoid tissue environment promotes activation of B cell antigen receptor (BCR) signaling pathways and CLL proliferation [6]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have